Leer en Español
Drugmakers Pfizer and BioNTech said Monday that three doses of their Covid-19 vaccine offer a strong immune response in children aged 6 months to 5 years.
The companies stressed that, according to the information gathered in their clinical trials, the three doses meet the criteria required for emergency approval by the health authorities. The suggestion is not polemic-free, as several studies have shown that children are not a population at risk for Covid-19.
The release states that 1,678 children well tolerated the third dose of 3 micrograms under five years of age with a safety profile similar to placebo.
According to its release, most adverse events were mild or moderate.
Pfizer’s CEO, Albert Bourla, said that following these data, they hope to soon complete their application to health regulators around the world to get their vaccine approved for that age range.
Last April, Moderna applied to U.S. and European health authorities for emergency authorization of its Covid-19 vaccine for children between the ages of six months and six years, becoming the first company to request such approval for this age group.
